|
|
 |
|
|
|
Covance, with headquarters in Princeton, New Jersey, is one of the world’s largest and most comprehensive drug development services companies, with annual revenues greater than $2 billion, employees in more than 60 countries, and more than 11,000 employees worldwide.
 |
NONCLINICAL DEVELOPMENT
(Toxicology, Research Models, Chemistry, Discovery & Translational Services)
- Managed 141 active PM/MDG (138/3) compound development programs (89 IND/CTA enabling) which lead to 30 IND/CTA submissions (2011)
- Performed best-in-class productivity cycle times: FIA to FIH in 22 weeks
- Dedicated Capacity Agreements with several major pharma customers
- Greater than 2.5M sq ft of research space
|
 |
 |
CLINICAL DEVELOPMENT
(Clinical Pharmacology, Early Patient Studies,
Clinical Development (Phase II-III), Central Laboratories)
- Supported 50% of latest breakthrough cancer treatments
- Supported development of the top 25 currently marketed medicines
- Broad-based, scalable and market-leading, Biomarker capability
- Greater than 99% of samples received within stability
- More than 214 million laboratory tests managed for over 1.2 M patients at over 120,000 investigator sites in over 95 countries
- Five Clinical Pharmacology units with over 350 beds
|
 |
MARKET ACCESS
- Multi-site call center capabilities to improve patient access, retention, and loyalty, and help secure rapid market acceptance
- Premier provider of reimbursement consulting and health economics and outcomes research services that help identify, build, and sustain a product’s advantage in the marketplace
- Team of experts offering a full spectrum of risk management and REMS services
- Supported over 1,100 clients since 1988 in diverse therapeutic and diagnostic areas
|
|
|
|